US/UK/Canada

Share

Contacts

  • Probi
    Ideongatan 1A, 223 70 Lund
    +46(0)46-286 89 20
    https://www.probi.com
  • Anita Johansen

    Interim CEO & VP R&D


    +46 46 286 89 20
  • Basudha Bhattarai Johansson

    VP HR & Sustainability


    +46 46 286 89 20

    • Quotes

    A lot of virus and bacteria enter the body through the mucous membranes, where a majority of our immune system is located. Therefore, we believe that probiotics can play a vital role as delivery carrier.
    Professor Magnus Johansson
    This joint venture is an important step in our commercial efforts to address new and attractive market niches. Even in these turbulent times we see great opportunities to jointly build a successful business, based on our longstanding relationship and confidence in our respective abilities to create scientific and commercial success.
    Tom Rönnlund, CEO Probi
    “We are very excited about the results showing an opportunity to delay the progression of bone loss by using our probiotics in this healthy population, which potentially may lead to a reduced risk for osteoporosis.”
    Ole Søgaard Andersen, CEO of Probi
    We are very happy to initiate this development program together with a strong global partner in OTC. By combining Probi´s probiotic expertise with the pharma company's development resources and regulatory expertise, we will form a very strong team moving forward together.”
    Ole Søgaard Andersen CEO of Probi
    “We are proud to conclude that our largest clinical trial so far has successfully confirmed earlier clinical results. Interestingly, in subjects that did not experience any viral infection during the study period, there was an activation of the immune system measured already after 2 weeks of Probi Defendum® intake, indicating an alert and resilient immune system.”
    Peter Nählstedt, CEO Probi AB
    “It is extremely exciting to launch the new probiotic line - Probi Select™. Through the integration of Nutraceutix, Probi has established a complete probiotic offering with the Probi Premium, Probi Select and Probi LiveBac ranges. Probi is now a true “One stop shop” for any consumer goods company wanting to drive their position in the probiotic market”
    Niklas Bjärum, President Probi USA and Global Sales & Marketing Probi Group.
    I am very excited about this transforming acquisition. Nutraceutix is an excellent match for us. Probi and Nutraceutix have complementary business models, limited customer overlap and share strong entrepreneurial values. The acquision creates a strong platform to continue the growth story in the US and in the global market.
    Peter Nählstedt
    ”There has been strong growth in the North American and Asian probiotic markets the past few years. We now see a growing interest in Europe too, and our new distribution agreements clearly reflect this positive trend
    Niklas Bjärum, Vice President of Marketing & Sales
    Pick a time period -
    Tags ( Active)

    Q2 2024: Significant progress on strategic initiatives

    Important events during the second quarter · Net sales in Q2 amounted to SEK 178.9 m, corresponding to an increase of 25% compared to last year (23% adjusted for currency effects). · The EBITDA margin was 19%, corresponding to an increase of 10 percentage points compared to last year. · Probi and ProViva celebrated 30 years of collaboration, highlighting the success with ProViva's popular probiotic drinks containing Lp299v[®]. · Probi strengthened its presence in APAC by launching China Innovation Day, a customer-oriented event focused on fostering collaborations in the

    Q1 2024: Steady Progress in a Transitional Year

    Important events during the first quarter · Underlying sales were overall as expected, despite Q1 coming in 12% below Q1 LY (11% adjusted for currency effects) to SEK 152 m (172). The reduction compared to LY is primarily due to positive one-time effects from delayed deliveries in the Americas as a result of a severe snowstorm at the end of 2022. Additionally, APAC was affected by timing shifts in orders during the quarter. · The EBITDA margin amounted to 15% (28). Adjusted for the above-mentioned snowstorm the comparison year margin is 23%. · A new study showing synergistic

    New study showing true synergistic benefits of Clasado´s and Probi®’s synbiotic concept

    A study recently published highlights the findings from the combination of the two proprietary and well-documented ingredients Bimuno ® GOS and Probi Defendum ® which shown to significantly increase the production of lactate and short-chain fatty acids, specifically butyrate.   There is a rising interest and awareness in health and nutrition, and consumers seek ways to improve their digestive, immune, and overall health. Following probiotic supplements, synbiotic supplements (comprising of 2,900 products on the market today) remain the most developed category. Synbiotics challenges pure

    Q3 2023: New strategic focus and improved sales trend

    Important events during the third quarter ·  Net sales increased by 8% (6% adjusted for currency effects) to SEK 156 m (145). · The EBITDA margin amounted to 18% (25) or 20% adjusted for items affecting comparability. · New strategic focus areas and financial targets. · New clinical study in metabolic health shows clear benefits with Probi's bacterial strains, which opens up a new health area. · Third clinical trial of HEAL9™ published, strengthens evidence of improved cognitive performance. Important events after the end of the period · Launch of Probi[®] Sensia, a

    Q2 2023: Weak underlying market in the Americas and EMEA

    Important events during the second quarter · Net sales decreased by 18% (21% adjusted for currency effects) to SEK 144 m (175). · The EBITDA margin amounted to 9% (26) and was burdened by items affecting comparability. Adjusted for these, the EBITDA margin was 17%. · Approval of HEAL9™ in Thailand. Enables further expansion in APAC. · Takeover of distribution of our own brand Probi® in Sweden and entry into Norway with new agreements with pharmacies. · Exclusive distributor of BLIS K12™ and BLIS M18™ ingredients in the US and Canada as of August 1. · New partnership with

    Probi initiates partnership with Clasado for the development of synbiotics

    Probi has entered into a partnership with Clasado Biosciences ("Clasado"), a company renowned for its research and development of prebiotics and the multi-award-winning ingredient Bimuno[®] GOS. Clasado is a company renowned for its research in prebiotics, and their prebiotic product Bimuno[®] GOS holds a leading market position and is one of the most clinically studied prebiotic ingredients with over 20 clinical trials. The purpose of this partnership is to leverage Probi's and Clasado's market-leading and scientific portfolios in probiotics and prebiotics, respectively, to develop

    Q4 2022: Fourth quarter impacted by one-off items

    Important events during the fourth quarter · Net sales decreased by 15% (-27% adjusted for currency effects) to SEK 144 m (170) in Q4. Snowstorms in the USA delayed deliveries to the value of SEK 18 m in net sales. · The EBITDA margin amounted to 11% (32) in Q4. Adjusted for the delayed deliveries and one-off items, the EBITDA margin was 24%. · Probi will take over the distribution of its own brand Probi® from April 1, 2023. · Purchase of strain rights from American partners for faster commercialization of spores. · The Board appointed Anita Johansen as Interim CEO. New

    Q2 2022: Solid quarter with exchange rate fueled growth

    Important events during the second quarter · Net sales increased by 10% (-1% adjusted for currency effects) to SEK 175 m (158) in Q2 and amounted to SEK 329 m (329) for H1, which was on a par with previous year (-9% adjusted for currency effects). · The EBITDA margin was 26% (25) in Q2 and 26% (26) in H1. · Stable performance in all regions, strongest quarter since 2020 in APAC. · Increased investments in sales activities and build-up of sales organization in region Americas. · New skincare product based on by-product from production process, contributes to reduced

    Probi´s Annual General Meeting 2022

    On Probi´s Annual General Meeting on 5 May 2022, the following was resolved:                                  · The Annual General Meeting approved the Annual Report and the Board’s proposal on a dividend for the financial year 2021 corresponding to SEK 1.30 per share. The record date was set to 9 May 2022. · The Annual General Meeting discharged the Board members and the CEO from liability for the financial year 2021. · The Annual General Meeting resolved that the Board shall consist of five members without any deputies. The meeting re-elected the Board members Jean-Yves Parisot,

    Probi’s upcycled fermentation broth becomes the basis of a new skin care product

    By-product from Probi’s manufacturing of probiotic dietary supplements is used in a new skin care product to be launched by Symrise in April 2022. This new skin care business opportunity also provides other benefits for Probi[®]. By upcycling valuable fermentation media from probiotic fermentation, we improve both production profitability and reduce our environmental footprint, while commercializing a new ingredient. Probi has for a long time worked closely with Symrise in various areas which has now resulted in a new skin care ingredient. SymFerment[®] is a moisturizing active

    Probi completes first production batches of dairy-free BLIS K12

    Probi[®] has completed the first commercial production batches of a dairy-free Streptococcus salivarius BLIS K12 at its US manufacturing site. The new BLIS[®] strains will shortly be offered to customers around the world. Probi entered a strategic partnership with New Zealand based Blis Technologies Ltd. as part of a long-term strategic collaboration in July, 2021. As part of this partnership, Probi[®] and Blis signed a licensing and distribution agreement. Probi is now manufacturing BLIS[®] strains at its recently upgraded fermentation facility in Redmond, WA and will shortly be

    Notice to Annual General Meeting in Probi AB (publ)

    The shareholders of Probi AB (publ), reg. no. 556417-7540, are hereby officially convened to the Annual General Meeting (“AGM”) which will be held on Thursday, 5 May 2022 at 3:00 p.m. at Elite Hotel, Ideon Gateway, Scheelevägen 27, Lund, Sweden. The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the AGM also by postal voting in accordance with the provisions in Probi’s Articles of Association. Right to participate and notification Participation in the meeting room A) Anyone wishing to attend the meeting room in person or through

    Q4 2021: Strong development in EMEA, Americas affected by customer dynamics

    Significant events during the fourth quarter · Net sales decreased by 8% (-9% adjusted for currency effects) to SEK 170 m (185). · The EBITDA margin was 32% (25%). · Strong performance in EMEA and APAC during the quarter, while the Americas continued to be affected by earlier communicated customer dynamics. Significant events during full-year 2021 · Net sales decreased by 8% (-3% adjusted for currency effects) to SEK 658 m (717). · The EBITDA margin was 28% (27%). · Several important partnerships were entered during the year, including Oriflame and Sinopharm Foreign

    Q3 2021: Regional dynamics affecting the quarter

    Significant events during the third quarter · Net sales decreased by 18% (-17% adjusted for currency changes) to SEK 159 m (195) in Q3 and decreased by 8% (-1% adjusted for currency changes) to SEK 488 m (532) for the first nine months of the year. The comparative period was positively affected by non-recurring income of around SEK 15 m. · The EBITDA margin was 27% (32%) in Q3 and 26% (28%) for the first nine months of the year. · Work started with Blis Technologies for the start of production and collaboration in the sales organization and R&D. · First tolerance study of two

    Presentation of Probi’s Q3 report 2021

    Probi’s report for the third quarter 2021 will be published on Friday, 22 October at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Tom Rönnlund and CFO Henrik Lundkvist will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://tv.streamfabriken.com/probi-q3-2021 The presentation can also be followed via a telephone conference on the following telephone number:Sweden: +46 8 50 55 83 59UK: +44 33 33

    Good tolerance in newborns of two specific probiotic strains from Probi[®]

    Probi[®] has performed one of the first tolerance studies with both a L. plantarum strain and a L. rhamnosus strain in a newborn population. L. plantarum has not been studied in an infant population this young before. The youngest baby in the study was recruited already at 4 days of age and started consuming probiotics at 11 days of age. The primary objective of this parallel, double blind, randomized, placebo-controlled pilot study was to evaluate the tolerance of L. plantarum HEAL9 (HEAL9[TM]) and L. rhamnosus 271 in healthy infants. The study has now been published. https://pubmed.

    Q2 2021: Probi enters new strategic partnerships

    Significant events during the second quarter · Net sales decreased by 12% (-3% adjusted for currency changes) to SEK 158 m (180) in Q2 and decreased by 3% (+8% adjusted for currency changes) to SEK 329 m (338) in H1. · EBITDA margin was 25% (32%) in Q2 and 26% (26%) in H1. · New partnership with Oriflame and launch of product based on Probi Digestis®. · New long-term research collaboration focusing on vaginal health with the Estonian company Tervisetehnoloogiate Arenduskeskus AS. · The number of shares and voting rights has been reduced by cancellation of the 250,000

    Probi acquires newly issued shares in New Zealand's Blis Technologies and enters into a strategic partnership

    Probi has invested approximately NZD 9 million in newly issued shares in Blis Technologies Ltd, corresponding to a 13% ownership. The investment is part of a long-term strategic collaboration between the companies. Blis Technologies, which is listed on the New Zealand stock exchange NZX, is an innovative probiotic company with clinically documented bacterial strains for supporting our natural immune defense, preventing infections of the mouth and throat. The strains also contribute to a healthy set of teeth and gums. Blis’ clinically documented strains have a long and successful history

    Probi and Oriflame enter partnership for digestive probiotic concept launch

    Two Swedish companies are teaming up in a partnership with focus on the Swedish heritage of innovation, natural ingredients and high-quality products. The probiotic supplier, Probi[®] and Oriflame have entered into agreement of a global launch of a probiotic supplement within general gut health. The product contains a scientifically proven probiotic strain with documented health effects and is a customer specific formulation, based on Probi’s concept called Probi Digestis[®]. Hrvoje Rein, Global Senior Brand Manager of Wellness by Oriflame says: “We are excited to be working with

    Improved probiotic products for women’s health – an unmet market need

    Probi[®] enters into a probiotic research partnership with focus on vaginal health Probi[®] and Tervisetehnoloogiate Arenduskeskus AS, Estonia, also known as the Competence Centre on Health Technologies (CCHT), have signed a long-term Research and Development collaboration agreement aimed to develop novel products based on probiotic lactobacilli strains. As part of the collaboration Probi will get specific access to a unique and proprietary bacterial strain library. Professor Reet Mändar (CCHT and University of Tartu), who has longstanding expertise within this health area expresses

    Change in the number of shares and votes in Probi

    In accordance with the resolution at the Annual General Meeting of Probi AB (publ) on May 7, 2021, the number of shares and votes in Probi has decreased during May 2021 through the cancellation of 250,000 own shares. Prior to the cancellation of own shares, there were a total of 11,644,125 shares and votes in Probi. The number of shares and votes decreased through the withdrawal by 250,000. Following the completion of the withdrawal, there are a total of 11,394,125 shares and votes in Probi as of May 31, 2021. For further information, please contact: Henrik Lundkvist, CFO: tel + 46

    Probi and China National Pharmaceutical Foreign Trade Corporation have signed a License & Supply Agreement

    This press release was originally released on 29th March 2021. The correct, full name of China National Pharmaceutical Foreign Trade Corporation and changes to the company description and quotes are hereby updated. The Swedish probiotic supplier, Probi[®] and China National Pharmaceutical Foreign Trade Corporation (SINOPHARM FORIGN TRADE), a wholly-owned subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM), has entered a partnership to expand the offering of premium probiotic offerings in the Chinese market on Feb 5th, 2021. SINOPHARM FORIGN TRADE will launch

    Iron status in healthy pregnant women improved by the probiotic Probi FerroSorb® concept

    Iron deficiency is the most common micronutrient deficiency and a global health problem. It is a very common challenge for women of childbearing age in general and especially for pregnant women. Therefore, many women start taking food supplements when they become pregnant. However, conventional high dose iron supplements commonly cause side effects like stomach pain and constipation. Thus, a more physiological approach for improving iron status is attractive when developing a new and safe product with clinical evidence. The previously reported study on improved iron status in healthy

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media